Better Health
Jan 12, 2021
| 4 min read

Better Health for more people: Our journey continues

The year 2020 was challenging for all of us. More than ever, we welcome the brighter prospects expected in 2021. Even if the coronavirus pandemic will certainly continue to influence our work, other challenges are also awaiting us. Here is a short overview of some of the exciting areas that we are looking forward to in 2021.

This article is posted on Sartorius Blog.

Life science research and innovation

Many diseases, such as cancer, dementia or inflammatory diseases, are still incurable. Although global medical knowledge is expected to double within a few years, the development of new drugs is becoming increasingly lengthy and costly. With innovative tools and technologies, Sartorius enables life science research and the biopharmaceutical industry to achieve relevant results faster, simplifying production and increasing the safety and efficiency of production processes.

Coronavirus vaccine

More than 200 companies, universities and institutes worldwide are working on the development of a coronavirus vaccine. Most of them work with Sartorius products. We will continue to bring our broad experience and portfolio of solutions to help our customers at all stages of vaccine development and production – from discovery and testing to large-scale manufacturing – while maintaining quality and flexibility at this accelerated speed.

Manufacturing capacities

In all regions, we are working on adapting our capacities to meet rising demand, especially for cell culture media, membranes and bioprocess equipment. New manufacturing capacities are being built in Germany and Puerto Rico. We are also strengthening customer relationships, for example, through new Customer Interaction Centers in our two focal regions of China and the U.S. Sartorius will thus enable clients to test equipment directly at our site, prior to delivery and installation at their plants.

Integration of acquisitions

Our recent acquisitions of WaterSep BioSeparations, BIA Separations, Biological Industries and selected life science assets from Danaher have significantly strengthened our portfolio. Whether on site or by remote connectivity, we will continue the successful integration of teams and technologies and grow together to form a strong and creative global team. Moreover, acquisitions will remain part of our strategy to meaningfully expand our product portfolio across the entire biopharmaceutical value chain.

Expansion of our team

As our company is growing dynamically, we are expanding our team with people who share our ambition and bring their skills to our vibrant, innovative environment. We currently have more than 600 open positions throughout the Group and are looking to fill these with ambitious and creative colleagues who are eager to make an impact.

Sustainable sourcing

Since the beginning of this year, Sartorius has been sourcing the energy needs of its locations in Germany from hydroelectric power. Conversion to renewable energy will thus enable us to reduce our CO2 emissions by 30 percent. This step is part of our sustainability strategy aimed at achieving far-reaching decarbonization and reducing consumption of resources. We are also planning to switch over progressively to renewable energy sources at our international sites.

Advanced Therapies

Advanced therapy medicinal products (ATMPs) describe a group of novel and highly complex drugs that have huge potential for the future of medicine. These include gene and cell therapeutics as well as engineered tissue products. Research is currently being conducted on cancer therapies as well as on infectious diseases, hereditary diseases and many others. At Sartorius, our team of specialists in these fields are closely tracking and supporting these developments.

Artificial Intelligence

Just recently, Sartorius became a shareholder of the German Research Center for Artificial Intelligence (DFKI). We are convinced that AI will fundamentally change research and development in the life science sector and enable new research approaches. Sartorius is currently working on deep and reinforcement learning for real-time cell analysis and on the simulation of biopharmaceutical production processes.

For related stories, visit the Sartorius Blog or follow us on LinkedIn.

Media Contact